𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II trial of recombinant interferon-alpha-2a and eflornithine in patients with recurrent glioma

✍ Scribed by Jan C. Buckner; Patrick A. Burch; Terrence L. Cascino; Judith R. O'Fallon; Bernd W. Scheithauer

Book ID
110230005
Publisher
Springer US
Year
1998
Tongue
English
Weight
26 KB
Volume
36
Category
Article
ISSN
0167-594X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Interferon-alpha antibodies in patients
Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial
✍ Otto PrΓΌmmer; Delta-P Study Group πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 657 KB

Background. Prolonged therapy with interferon (IFN) may lead to the formation of IFN antibodies. Methods. Patients with renal cell carcinoma (n = 270) with advanced localized disease were randomized after complete tumor resection to receive treatment with adjuvant recombinant IFN-alpha-2a (rIFN-a2a

A Phase II trial of 5-fluorouracil and r
A Phase II trial of 5-fluorouracil and recombinant alpha-2a-interferon in previously untreated metastatic gastric carcinoma
✍ Richard Pazdur; Jaffer A. Ajani; Rodger Winn; James Bearden; Robert J. Belt; Sus πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 468 KB πŸ‘ 3 views

A Phase I1 clinical trial of the combination of 5-fluorouracil (5-FU) and recombinant alpha-2a-interferon (a-2a-IFN) was conducted in 44 patients. Patients had not received chemotherapy previously and had measurable metastatic gastric carcinoma. 5-FU was administered as a continuous infusion at a do